Bioequivalence and Bioavailability Forum 01:06 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

FDA-Subject by formulation interaction (Switchability) [Regulatives / Guidelines]

posted by sudy - India, 2018-03-28 07:09  - Posting: # 18598
Views: 1,490

Dear all,

I have a discussion point regarding switchability criteria for methylphenidate 54mg tabs (specially). For lower strength, they have removed this criterion.

As per guideline, we have to meet the ABE criteria and additionally meet 95% UB for switchability.

Now, as we are doing a fully replicate study as suggested by OGD recommendation on methylphenidate, can we use RSABE approach in case if we get ISCV-reference > 30% for any one of the PK parameter Cmax or partial AUCs, instead of using 90% CI calculation to prove the bioequivalence?

The OGD recommendation did not discuss anything about this case, as we know that methylphenidate is not a HVD. But incase if we got CV-R more than 30%, can we apply RSABE?

Your suggestion will be highly appreciated.

Regards,
Sudy

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,037 posts in 4,061 threads, 1,300 registered users;
online 12 (0 registered, 12 guests [including 12 identified bots]).

An expert is a man who has made all the mistakes,
which can be made, in a very narrow field.    Niels Bohr

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed